<p>/PRNewswire/ -- Avid Bioservices, Inc.（艾维德生物服务公司），一家领先的生物制剂合同开发和制造组织（CDMO），今天宣布任命 Kenneth Bilenberg 为其新任首席执行官（CEO）。Bilenberg 是一位拥有超过 20 年经验的资深行业高管，最近担任富士胶片生物技术公司的首席运营官，负责全球各类业务的运营，在此之前曾在诺和诺德担任高级领导职务。他目前居住在丹麦，并将在可能时迁往加利福尼亚。他接替因健康原因辞职的 Nick Green，后者在艾维德经历强劲增长期间提供了指导。</p>
<p>继续阅读</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null"/></p>
<p>Avid Bioservices 的首席执行官 Kenneth Bilenberg</p>
<p>&#34;在这个过程中，帮助找到合适的领导者以推动艾维德进入下一个阶段对我来说非常重要，&#34;Green 说。&#34;在 Kenneth 身上，我们找到了具有关键行业经验、强大愿景和真正欣赏艾维德文化的人。我相信公司在优秀的领导下。&#34;</p>
<p>&#34;董事会非常高兴地欢迎 Kenneth Bilenberg 成为我们的新 CEO，&#34;董事会在给员工的声明中说。&#34;Kenneth 在扩大组织规模和在国际市场上交付复杂项目方面拥有深厚的专业知识，这使他成为引领艾维德走向未来的理想人选。我们还对 Nick Green 的远见卓识表示最深切的感谢，他的领导使公司实现了显著增长、提升了能力，并建立了持久的卓越文化。&#34;</p>
<p>&#34;很少有公司像艾维德一样在质量、监管记录和交付表现方面脱颖而出——始终将患者、客户和员工置于中心，&#34;Kenneth Bilenberg 说。</p>
<p>&#34;能够加入艾维德并为其成为全球生物制造解决方案领导者的愿景做出贡献，我感到非常荣幸。无论是从 DNA 到 IND 的可预测路径，还是推进到 BLA 和商业准备，或是在大规模供应治疗方案方面，艾维德都处于为全球客户提供服务的良好位置。&#34;</p>
<p>&#34;与艾维德团队一起，我们将以可预测性、信任和超越客户期望为重点，建立在这一坚实基础之上。我的近期优先事项包括：</p>
<ul>
<li>为现有客户持续提供可预测和强劲的交付</li>
<li>支持全球生物制药的回流和区域供应策略</li>
<li>扩大艾维德的产能以满足日益增长的全球需求</li>
</ul>
<p>从长远来看，艾维德的基础——在 GHO 和 Ampersand 的生命科学投资组合的支持下——使其成为行业中最令人兴奋的机会之一。从概念到商业化，我们致力于帮助客户将最复杂的生物治疗方案带给全球患者。&#34;</p>
<p>在 Bilenberg 的领导下，艾维德准备在其基础上进一步发展，扩大其能力，并作为值得信赖的合作伙伴在全球范围内推进生物制剂的应用。</p>
<p><strong>关于艾维德生物服务</strong></p>
<p>艾维德生物服务是一家全球合同开发和制造组织（CDMO），专注于哺乳动物细胞培养制造。总部位于美国，拥有无可挑剔的 FDA 记录，艾维德因其灵活性、质量和应对复杂全球监管环境的能力而受到全球生物制药创新者的信任。艾维德拥有支持新兴生物技术和大型跨国制药公司的经验，提供从开发到商业供应的端到端解决方案。</p>
<p>艾维德的数字：</p>
<ul>
<li>制造超过 575 批次</li>
<li>全球交付超过 250 批商业产品</li>
<li>5 个以上获得批准的商业产品</li>
<li>在主要监管机构进行 10 次成功的预批准/预许可检查</li>
</ul>
<p>来源：Avid Bioservices</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwOTE1Jk5ld3NJdGVtSWQ9TEE3MzE3NyZUcmFuc21pc3Npb25fSWQ9MjAyNTA5MTUwODA1UFJfTkVXU19VU1BSX19fX19MQTczMTc3?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwOTE1Jk5ld3NJdGVtSWQ9TEE3MzE3NyZUcmFuc21pc3Npb25fSWQ9MjAyNTA5MTUwODA1UFJfTkVXU19VU1BSX19fX19MQTczMTc3"/></p>

CDMO

<p>Avid Bioservices, Inc. 任命 Kenneth Bilenberg 为新任首席执行官，接替因健康原因辞职的 Nick Green。Bilenberg 拥有超过 20 年的行业经验，曾担任富士胶片生物技术公司的首席运营官。董事会对 Bilenberg 能够引领 Avid 进入下一个发展阶段充满信心，重点关注可预测的交付、支持生物制药的回流以及扩大产能以满足全球需求。Avid 在生物制造解决方案方面以其质量和监管记录而闻名</p>

<p>, /PRNewswire/ -- Avid Bioservices, Inc., a leading biologics contract development and manufacturing organization (CDMO), today announced the appointment of Kenneth Bilenberg as its new Chief Executive Officer (CEO). A seasoned industry executive with more than 20 years of experience, Bilenberg most recently served as Chief Operating Officer of Fujifilm Biotechnologies, leading global operations across modalities and scale, and prior to that held senior leadership roles at Novo Nordisk. He is currently based in Denmark and will be relocating to California when possible. He succeeds Nick Green, who is stepping down for health reasons after guiding Avid through a period of strong growth.</p>
<div class="lb-trans"><p>/PRNewswire/ -- Avid Bioservices, Inc.（艾维德生物服务公司），一家领先的生物制剂合同开发和制造组织（CDMO），今天宣布任命 Kenneth Bilenberg 为其新任首席执行官（CEO）。Bilenberg 是一位拥有超过 20 年经验的资深行业高管，最近担任富士胶片生物技术公司的首席运营官，负责全球各类业务的运营，在此之前曾在诺和诺德担任高级领导职务。他目前居住在丹麦，并将在可能时迁往加利福尼亚。他接替因健康原因辞职的 Nick Green，后者在艾维德经历强劲增长期间提供了指导。</p>
</div><p>Continue Reading</p>
<div class="lb-trans"><p>继续阅读</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null" alt="" original-src="https://www.prnewswire.com/news-releases/null"/></p>
<p>Kenneth Bilenberg, CEO of Avid Bioservices</p>
<div class="lb-trans"><p>Avid Bioservices 的首席执行官 Kenneth Bilenberg</p>
</div><p>&#34;Throughout this process, it was important to me to help identify the right leader to advance Avid into its next chapter,&#34; said Green. &#34;In Kenneth, we found someone with key industry experience as well as a strong vision and a true appreciation for Avid's culture. I am confident the company is in excellent hands.&#34;</p>
<div class="lb-trans"><p>&#34;在这个过程中，帮助找到合适的领导者以推动艾维德进入下一个阶段对我来说非常重要，&#34;Green 说。&#34;在 Kenneth 身上，我们找到了具有关键行业经验、强大愿景和真正欣赏艾维德文化的人。我相信公司在优秀的领导下。&#34;</p>
</div><p>&#34;The board of directors is delighted to welcome Kenneth Bilenberg as our new CEO,&#34; the board said in a statement to staff. &#34;Kenneth brings deep expertise in scaling organizations and delivering complex programs across international markets, which makes him an ideal choice to lead Avid into the future. We also extend our deepest gratitude to Nick Green for his visionary leadership, which has enabled significant growth, advanced capabilities, and a culture of excellence that will endure.&#34;</p>
<div class="lb-trans"><p>&#34;董事会非常高兴地欢迎 Kenneth Bilenberg 成为我们的新 CEO，&#34;董事会在给员工的声明中说。&#34;Kenneth 在扩大组织规模和在国际市场上交付复杂项目方面拥有深厚的专业知识，这使他成为引领艾维德走向未来的理想人选。我们还对 Nick Green 的远见卓识表示最深切的感谢，他的领导使公司实现了显著增长、提升了能力，并建立了持久的卓越文化。&#34;</p>
</div><p>&#34;Few companies stand out the way Avid does for its quality, regulatory track record, and delivery performance — always keeping patients, clients, and people at the center,&#34; said Kenneth Bilenberg.</p>
<div class="lb-trans"><p>&#34;很少有公司像艾维德一样在质量、监管记录和交付表现方面脱颖而出——始终将患者、客户和员工置于中心，&#34;Kenneth Bilenberg 说。</p>
</div><p>&#34;It is an honor to join Avid and to contribute to its vision of becoming a global leader in biomanufacturing solutions. Whether enabling predictable pathways from DNA to IND, advancing to BLA and commercial readiness, or supplying therapies at scale, Avid is well positioned to deliver for clients worldwide.&#34;</p>
<div class="lb-trans"><p>&#34;能够加入艾维德并为其成为全球生物制造解决方案领导者的愿景做出贡献，我感到非常荣幸。无论是从 DNA 到 IND 的可预测路径，还是推进到 BLA 和商业准备，或是在大规模供应治疗方案方面，艾维德都处于为全球客户提供服务的良好位置。&#34;</p>
</div><p>&#34;Together with the Avid team, we will build on this strong foundation with a focus on predictability, trust, and exceeding client expectations. My near-term priorities include:</p>
<div class="lb-trans"><p>&#34;与艾维德团队一起，我们将以可预测性、信任和超越客户期望为重点，建立在这一坚实基础之上。我的近期优先事项包括：</p>
</div><ul>
<li>Continuing predictable and strong delivery for existing clients</li>
<li>Supporting global biopharma reshoring and regional supply strategies</li>
<li>Expanding Avid's capacity to meet growing worldwide demand</li>
</ul>
<div class="lb-trans"><ul>
<li>为现有客户持续提供可预测和强劲的交付</li>
<li>支持全球生物制药的回流和区域供应策略</li>
<li>扩大艾维德的产能以满足日益增长的全球需求</li>
</ul>
</div><p>Longer term, Avid's foundation — supported by GHO and Ampersand's life sciences portfolio — makes this one of the most exciting opportunities in the industry. From concept to commercialization, we are committed to helping our customers bring the most complex biologic therapies to patients across the globe.&#34;</p>
<div class="lb-trans"><p>从长远来看，艾维德的基础——在 GHO 和 Ampersand 的生命科学投资组合的支持下——使其成为行业中最令人兴奋的机会之一。从概念到商业化，我们致力于帮助客户将最复杂的生物治疗方案带给全球患者。&#34;</p>
</div><p>Under Bilenberg's leadership, Avid is poised to build on its foundation, expand its capabilities, and thrive as a trusted partner in advancing biologics to patients worldwide.</p>
<div class="lb-trans"><p>在 Bilenberg 的领导下，艾维德准备在其基础上进一步发展，扩大其能力，并作为值得信赖的合作伙伴在全球范围内推进生物制剂的应用。</p>
</div><p><strong>About Avid Bioservices</strong></p>
<div class="lb-trans"><p><strong>关于艾维德生物服务</strong></p>
</div><p>Avid Bioservices is a global contract development and manufacturing organization (CDMO) specializing in mammalian cell-culture manufacturing. Headquartered in the U.S. with a flawless FDA record, Avid is trusted by biopharmaceutical innovators worldwide for its agility, quality, and ability to navigate complex global regulatory landscapes. With experience supporting both emerging biotech and large multinational pharma companies, Avid provides end-to-end solutions from development through commercial supply.</p>
<div class="lb-trans"><p>艾维德生物服务是一家全球合同开发和制造组织（CDMO），专注于哺乳动物细胞培养制造。总部位于美国，拥有无可挑剔的 FDA 记录，艾维德因其灵活性、质量和应对复杂全球监管环境的能力而受到全球生物制药创新者的信任。艾维德拥有支持新兴生物技术和大型跨国制药公司的经验，提供从开发到商业供应的端到端解决方案。</p>
</div><p>Avid By the Numbers:</p>
<div class="lb-trans"><p>艾维德的数字：</p>
</div><ul>
<li>More than 575 batches manufactured</li>
<li>Over 250 commercial batches delivered globally</li>
<li>5+ approved commercial products</li>
<li>10 successful pre-approval/pre-license inspections across major regulatory agencies</li>
</ul>
<div class="lb-trans"><ul>
<li>制造超过 575 批次</li>
<li>全球交付超过 250 批商业产品</li>
<li>5 个以上获得批准的商业产品</li>
<li>在主要监管机构进行 10 次成功的预批准/预许可检查</li>
</ul>
</div><p>SOURCE Avid Bioservices</p>
<div class="lb-trans"><p>来源：Avid Bioservices</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwOTE1Jk5ld3NJdGVtSWQ9TEE3MzE3NyZUcmFuc21pc3Npb25fSWQ9MjAyNTA5MTUwODA1UFJfTkVXU19VU1BSX19fX19MQTczMTc3" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=LA73177&amp;Transmission_Id=202509150805PR_NEWS_USPR_____LA73177&amp;DateId=20250915"/></p>

Avid Bioservices 欢迎 Kenneth Bilenberg 出任新任首席执行官